Corpus overview


Overview

MeSH Disease

Human Phenotype

Pneumonia (7)

Dyspnea (3)

Fever (2)

Overweight (1)

Obesity (1)


Transmission

Seroprevalence
    displaying 1 - 7 records in total 7
    records per page




    Overweight HP/ obesity HP obesity MESHD as the potentially most important lifestyle factor associated with signs of pneumonia HP pneumonia MESHD in COVID-19

    Authors: Vanessa Sacco; Barbara Rauch; Christina Gar; Stefanie Haschka; Anne L Potzel; Stefanie Kern-Matschilles; Friederike Banning; Irina Benz; Mandy Meisel; Jochen Seissler; Andreas Lechner

    doi:10.1101/2020.07.23.20161042 Date: 2020-07-24 Source: medRxiv

    Objective The occurrence of pneumonia HP pneumonia MESHD separates severe cases of COVID-19 from the majority of cases with mild disease. However, the factors determining whether or not pneumonia HP develops remain to be fully uncovered. We therefore explored the associations of several lifestyle factors with signs of pneumonia HP pneumonia MESHD in COVID-19. Methods Between May and July 2020, we conducted an online survey of 201 adults TRANS in Germany who had recently gone through COVID-19, predominantly as outpatients. Of these, 165 had a PCR-based diagnosis and 36 had a retrospective diagnosis by antibody testing SERO. The survey covered demographic information, eight lifestyle factors, comorbidities and medication use. We defined the main outcome as the presence vs. the absence of signs of pneumonia HP pneumonia MESHD, represented by dyspnea HP dyspnea MESHD, the requirement for oxygen therapy or intubation. Results Signs of pneumonia HP pneumonia MESHD occurred in 39 of the 165 individuals with a PCR-based diagnosis of COVID-19 (23.6%). Among the lifestyle factors examined, only overweight HP/ obesity HP obesity MESHD associated with signs of pneumonia HP pneumonia MESHD (odds ratio 2.68 (1.29 - 5.59) p=0.008). The observed association remained significant after multivariate adjustment, with BMI as a metric variable, and also after including the antibody SERO-positive individuals into the analysis. Conclusions This exploratory study finds an association of overweight HP/ obesity HP obesity MESHD with signs of pneumonia HP pneumonia MESHD in COVID-19. This finding suggests that a signal proportional to body fat mass, such as the hormone leptin, impairs the body's ability to clear SARS-CoV-2 before pneumonia HP develops. This hypothesis concurs with previous work and should be investigated further to possibly reduce the proportion of severe cases of COVID-19.

    SEROPREVALENCE SERO AND CLINICAL SPECTRUM OF SARS-CoV-2 INFECTION IN MESHD THE FIRST VERSUS THIRD TRIMESTER OF PREGNANCY

    Authors: Francesca Crovetto; Fatima Crispi; Elisa Llurba; Francesc Figueras; Maria Dolores Gomez-Roig; Eduard Gratacos

    doi:10.1101/2020.06.17.20134098 Date: 2020-06-19 Source: medRxiv

    Introduction: Case registries of pregnant women diagnosed with coronavirus disease MESHD (COVID-19) by polymerase chain reaction (PCR) have reported that the majority experienced mild infection MESHD, but up to 9% may require critical care. Most COVID-19 cases published were in the third trimester of pregnancy, which could reflect reporting bias, higher risk of infection TRANS risk of infection TRANS infection MESHD or increased disease severity in late pregnancy. Seroprevalence SERO studies may allow reliable estimates of the susceptibility to infection MESHD and clinical spectrum since they include asymptomatic TRANS and mild infections not tested for PCR. We evaluated the seroprevalence SERO and clinical presentation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD in pregnant women in the first and third trimester. Methods: The study was approved by the Institutional Review Board at each institution and informed consent was obtained. We recruited 874 consecutive pregnancies attending for first trimester screening (10-16 weeks of gestation, n=372) or delivery (n=502) from April 14 to May 5. All women were interviewed with a structured questionnaire for COVID-19 symptoms two months prior to sampling. SARS-CoV-2 IgG and IgM/IgA antibodies were tested SERO (COVID-19 VIRCLIA Monotest, Vircell Microbiologist, Spain; reported sensitivity SERO 70% IgG and 89% IgM/IgA, and specificity 89% and 99% respectively). Indeterminate results were re-tested (VITROS Immunodiagnostic Products Anti-SARS-CoV2 Total Tests, Ortho Clinical Diagnostics, USA; 100% sensitivity SERO and specificity) and re-classified as positive or negative. Women with COVID-19 were diagnosed and managed according to standard protocols and guidelines3,4. Statistical differences were tested using the {chi}2 test or Student t-test as appropriate (p<0.05). Results: A total of 125 of 874 women (14.3%) were positive for either IgG or IgM/IgA SARS-CoV-2 antibodies SERO, 54/372 (14.5%) in the first and 71/502 (14.1%) in the third trimester. A total of 75/125 (60%) reported no symptoms of COVID-19 in the past 2 months, whereas 44 (35.2%) reported one or more symptoms, of which 31 (24.8%) had at least 3 symptoms or anosmia HP anosmia MESHD and 8 (6.4%) dyspnea HP dyspnea MESHD. Overall, 7 women (5.6%) were admitted for persistent fever HP fever MESHD despite paracetamol and dyspnea HP dyspnea MESHD, of which 3 had signs of pneumonia HP pneumonia MESHD on chest radiography. All 3 had criteria for severity (bilateral chest condensation, respiratory rate>30 and leukopenia HP leukopenia MESHD) and required oxygen support but not critical care or mechanical ventilation, and they were all discharged well. The rates of symptomatic infection MESHD, hospital admission or dyspnea HP dyspnea MESHD were significantly higher in third trimester women (Table and Figure). Discussion: The 14.3% seroprevalence SERO of SARS-COV-2 in pregnant women in this study was substantially larger than the contemporary rates of PCR positive cases (0.78%) reported for women 20-40y in Barcelona. The data confirm that COVID-19 is asymptomatic TRANS in the majority of pregnant women6 and illustrate the value of seroprevalence SERO studies to capture the high proportion of asymptomatic TRANS or mild infections MESHD. In this study, none of the 125 pregnant women with SARS-CoV-2 infection MESHD required critical care as compared to 9% reported in cases diagnosed with PCR. However, the proportion of infections MESHD with symptoms or dyspnea HP dyspnea MESHD was remarkably higher in the third trimester, and these results are in line with COVID-19 registries, reporting that 81% of hospitalized women were in late pregnancy or peripartum. These results provide reassuring information that, even in settings with a high prevalence SERO, SARS-CoV-2 infection MESHD in pregnancy mostly presents with asymptomatic TRANS or mild clinical forms. The susceptibility to infection seemed to be the same in the first and the third trimesters of gestation. The data further suggest that, as with other respiratory viruses, COVID-19 could be more severe and require increased surveillance in late pregnancy. These findings should be confirmed and extended with larger consecutive prevalence SERO studies in pregnancy.

    SARS-CoV-2 Serology Results in the First COVID-19 Case in California: A Case Report and Recommendations for Serology Testing and Interpretation

    Authors: Richard B. Lanman, MD; Todd H. Lanman

    doi:10.21203/rs.3.rs-35358/v1 Date: 2020-06-12 Source: ResearchSquare

    Background: As countries in COVID-19 pandemic lockdown begin relaxation of shelter-in-place mitigation strategies, the role of serology testing escalates in importance. However, there are no clear guidelines as to when to use qualitative rapid diagnostic serology tests (RDTs) vs. SARS-CoV-2 viral RNA load (PCR) tests as an aid in acute diagnosis of patients presenting with flu-like symptoms, nor how to interpret serology test results in asymptomatic TRANS individuals or those with atypical COVID-19 symptomatology. Here we describe, in the context of the likely first case of COVID-19 in California, with an atypical presentation and not tested acutely, who nearly 3 months later was found to be IgM- and IgG+ positive for SARS-CoV-2 antibodies SERO, highlighting the role of RDT- based serology testing SERO and interpretation in retrospective diagnosis.Case Presentation: A 62-year-old male TRANS practicing neurosurgeon had onset of flu-like symptoms on January 20 with fatigue HP fatigue MESHD, slight cough HP only on deep inspiration, intermittent pleuritic chest pain MESHD chest pain HP unrelated to exertion, dyspnea HP dyspnea MESHD, and night sweats HP but without fever HP fever MESHD, sore throat or rhinorrhea HP rhinorrhea MESHD. He had recently traveled TRANS abroad but not to China. CT scan revealed right lower lobe infiltrate and effusion. Because of atypical symptoms, and low prevalence SERO of COVID-19 in January, community acquired pneumonia HP pneumonia MESHD was diagnosed and one week of doxycycline was prescribed without relief, followed by a second week of azithromycin with symptom remission. Three months later the physician-patient (author THL), tested positive for SARS-CoV-2 antibodies SERO by a serology point-of-care rapid diagnostic test (RDT).Conclusions: Serology testing may be an aid in acute diagnosis of COVID-19, especially in patients with atypical presentations, as well as in assessment of asymptomatic TRANS higher-risk persons such as healthcare workers for prior infection MESHD. Recommendations for serology testing and interpretation are explicated.

    The production of antibodies for SARS-CoV-2 SERO and its clinical implication

    Authors: Qianfang Hu; Xiaoping Cui; Xinzhu Liu; Bin Peng; Jinyue Jiang; Xiaohui Wang; Yan Li; Wenhui Hu; Zhi Ao; Jun Duan; Xue Wang; Linxiao Zhu; Shuliang Guo; Guicheng Wu

    doi:10.1101/2020.04.20.20065953 Date: 2020-04-24 Source: medRxiv

    Background: Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) MESHD, a novel betacoronavirus, has caused an outburst of pneumonia HP pneumonia MESHD cases in Wuhan, China. We report the production of specific IgM and IgG antibodies SERO after the infection of SARS-CoV-2 MESHD and its implication for the diagnosis, pathology and the course of the disease as well as the recurrence of positive nucleic acid tests after discharge. Methods: Test results for SARS-CoV-2 IgM MESHD IgM and IgG antibodies SERO of 221 confirmed COVID-19 patients were retrospectively examined, and their clinical data were collected and analyzed based on various subgroups. SARS-CoV-2 IgM and IgG antibodies SERO were determined with the chemiluminescence method. Findings: The concentration (S/CO) of SARS-CoV-2 IgM MESHD IgM and IgG antibodies SERO peaked on day 19-21 after symptom onset TRANS, with a median of 17.38 (IQR 4.39-36.4) for IgM and 5.59 (IQR 0.73-13.65) for IgG. Detection rates reached highest on day 16-18 and day 19-21 for IgM and IgG, which were 73.6% and 98.6%, respectively, with significantly higher concentration of IgG in critically ill MESHD patients than in those with mild to moderate disease (P=0.027). The concentration of the antibodies SERO on day 16-21 is not correlated with the course or outcome of the disease (Spearman r < 0.20, P > 0.05). Nasopharyngeal swabs revealed positive SARS-CoV-2 RNA in up to 52.7% of recovered patients after discharge, whose IgG proved to be significantly lower than that of those with negative RNA results (P = 0.009). IgG and IgM were tested twice within 14 days after discharge with a 7-day interval, and the second testing of these antibodies SERO displayed a decrease in concentration of 21.2% (IQR, 11.2%34.48%) for IgG and 23.05% (IQR, -27.96%46.13%) for IgM, without statistical significance between the patients with re-detectable positive RNA results and those with negative RNA results after discharge. However, those with positive results experienced a count decrease in lymphocyte subsets. Interpretation: The concentration of SARS-CoV-2 IgM MESHD IgM and IgG antibodies SERO peaked on day 19-21 after symptom onset TRANS, and antibody testing SERO on day 16-21 is associated with increased detection rates, but the antibody SERO concentration does not affect the course and outcome of the infection MESHD. Recovering patients with re-detectable positive SARS-CoV-2 RNA displayed lower concentration of IgG, but the downward trend of IgG during recovery indicated its limited duration of protection, and the protective effect of IgG remains to be investigated.

    Rapid diagnosis of SARS-CoV-2 infection MESHD by detecting IgG and IgM antibodies SERO with an immunochromatographic device: a prospective single-center study

    Authors: Felipe Perez Garcia; Ramon Perez Tanoira; Juan Pedro Romanyk Cabrera; Teresa Arroyo Serrano; Peña Gomez Herruz; Juan Cuadros Gonzalez

    doi:10.1101/2020.04.11.20062158 Date: 2020-04-15 Source: medRxiv

    Objectives: SARS-CoV-2 infection MESHD constitutes a diagnostic challenge in patients from 2-3 weeks after the onset of symptoms TRANS, due to the low positivity rate of the PCR, especially in upper respiratory samples. Serologic tests SERO based on ELISA SERO have been developed and evaluated as useful complements to PCR in these situations. However, there is scarce information about the usefulness of rapid tests SERO based on immunochromatography. The aim of our study was to analyze the diagnostic performance SERO of these rapid tests SERO in COVID-19 pneumonia HP pneumonia MESHD patients. Methods: We evaluated an immunochromatographic test (AllTest COV-19 IgG / IgM kit) which detects IgG and IgM antibodies SERO. First, we performed a validation of the serologic test SERO using serum samples SERO from 45 healthy control patients (group 1) and 55 confirmed by PCR cases of COVID-19 (group 2) in order to establish the specificity and sensitivity SERO, respectively. Then we prospectively employed the test in 63 patients diagnosed with pneumonia HP pneumonia MESHD of unknown etiology that were SARS-CoV-2 negative by PCR (group 3), to establish the diagnostic performance SERO in these patients. Results: All patients from group 1 (healthy controls) resulted negative for the serologic test SERO (specificity = 100%). Regarding group 2 (PCR positive) patients, the median time from the onset of symptoms TRANS was 11 days and the test was positive for either IgM or IgG in 26 out of 55 patients (overall sensitivity SERO = 47.3%). However, in those patients with 14 days or more from onset of symptoms TRANS, the sensitivity SERO was 73.9%. Regarding group 3 patients, the median days from onset of symptoms TRANS was 17 and the test was positive in 56 out of 63 patients (88.9% positivity rate). In these group 3 patients with 14 days or more from onset of symptoms TRANS, the positivity rate was 91.1%. Conclusions: Our study shows that serologic rapid tests SERO can be used as a complement of PCR to diagnose SARS-CoV-2 infection MESHD after 14 days from the onset of symptoms TRANS. These immunochromatographic devices could be especially useful in hospitalized patients with pneumonia HP pneumonia MESHD of unknown etiology with 14 or more days from the onset of symptoms TRANS and in whom the PCR has been negative.

    Evaluation the auxiliary diagnosis value of antibodies SERO assays for detection of novel coronavirus (SARS-Cov-2) causing an outbreak of pneumonia HP pneumonia MESHD (COVID-19)

    Authors: Yong Gao; Yi Yuan; Tuan Tuan Li; Wu Xiao Wang; Yong Xiu Li; Ang Li; Feng Ming Han

    doi:10.1101/2020.03.26.20042044 Date: 2020-03-30 Source: medRxiv

    Background: The spread of an novel coronavirus (SARS-CoV-2, previously named 2019-nCoV) has already taken on pandemic proportions, affecting over 100 countries in a matter of weeks. Elucidating the diagnostic value of different methods, especially the auxiliary diagnosis value of antibodies SERO assays for SARS-CoV-2 infection MESHD is helpful for improving the sensitivities SERO of pathogenic-diagnosis, providing timely treatment, and differentiating the infected cases from the healthy, thus preventing further epidemics. Methods: Medical records from 38 patients with confirmed SARS-CoV-2 infection MESHD in the Second People's Hospital of Fuyang from January 22, 2020 to February 28, 2020 were collected and retrospectively analyzed. Specimens including throat swabs, sputum and serum SERO were collected during the hospitalization period, viral RNAs and serum SERO IgM-IgG antibodies SERO to SARS-CoV-2 were measured respectively. The detectability of different methods as well as the auxiliary diagnosis value of antibodies test SERO for SARS-CoV-2 infection MESHD were analyzed. Results: Among 38 patients, the total seropositive rate for IgM and IgG was 50.0% and 92.1%, respectively. Two patients remained seronegative throughout the course of illness. In the early phase of illness, the RNA test for sputum specimens possessed the highest detectability(92.3%), followed by the the RNA test for throat swabs (69.2%), and the antibodies SERO assays presented lower positive rates(IgM, 23.0%, IgG, 53.8%). While, the sensitivity SERO of antibodies SERO assays overtook that of RNA test since day 8 after onset (IgM, 50.0%; IgG, 87.5%). Of note, the positive rate of throat swabs was only 13.0% for cases in later phase([≥]15 d.a.o), and the sensitivities SERO of IgM and IgG rose to 52.2% and 91.3%, respectively. Combined use of antibodies SERO assay and qRT-PCR at the same time was able to improve the sensitivities SERO of pathogenic-diagnosis, especially for the throat swabs group at the later stage of illness. Moreover, most of these cases with undetectable viral RNA in throat swabs specimens at the early stage of illness were able to be IgM/IgG seropositive after 7 days. Conclusions: The antibodies SERO detection against SARS-CoV-2 offers vital clinical information for physicians, and could be used as an effective supplementary indicator for suspected cases of negative viral nucleic acid detection or in conjunction with nucleic acid detection in the diagnosis of suspected cases.

    Evaluation of Enzyme-Linked Immunoassay SERO and Colloidal Gold- Immunochromatographic Assay SERO Kit for Detection of Novel Coronavirus (SARS-Cov-2) Causing an Outbreak of Pneumonia HP (COVID-19)

    Authors: Jie Xiang; Mingzhe Yan; Hongze Li; Ting Liu; Chenyao Lin; Shuang Huang; Changxin Shen

    doi:10.1101/2020.02.27.20028787 Date: 2020-03-01 Source: medRxiv

    Abstract BACKGROUND: In December 2019, a novel coronavirus (SARS-CoV-2) infected pneumonia MESHD pneumonia HP (COVID-19) occurred in Wuhan, China. Travel TRANS-associated cases have also been reported in other countries. The number of cases has increased rapidly but laboratory diagnosis is limited. METHODS: We collect two groups of cases diagnosed with COVID-19 for experiments. One group collected 63 samples for Enzyme-linked immunosorbent assay SERO ( ELISA) IgG SERO and IgM antibodies SERO. The other group collected 91 plasma SERO samples for colloidal gold-immunochromatographic assay SERO (GICA). RESULTS: The sensitivity SERO of the combined ELISA SERO IgM and ELISA IgG SERO detection was 55/63 ( 87.3%), The sensitivity SERO of the combined GICA IgM and GICA IgG detection was 75/91 ( 82.4%), Both methods are negative for healthy controls, specificity of 100% .There is no significant difference between the sensitivity SERO of between ELISA SERO and GICA (IgM+ IgG). CONCLUSIONS: ELISA SERO and GICA for specific IgM and IgG antibodies SERO are conventional serological assays SERO, they are simple, fast, and safe, the results can be used for clinical reference, and the huge clinical diagnosis and treatment pressure can be greatly relieved.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.